Last updated: February 19, 2026
Quizartinib dihydrochloride (AC220) is a potent, selective FLT3 inhibitor developed by Daiichi Sankyo. It targets the FMS-like tyrosine kinase 3 (FLT3) receptor, which is mutated in approximately 20-30% of acute myeloid leukemia (AML) patients. These mutations, particularly internal tandem duplications (ITDs), are associated with poor prognosis.
What is the current status of quizartinib dihydrochloride's clinical development?
Quizartinib dihydrochloride has advanced through multiple phases of clinical trials, demonstrating significant efficacy in specific AML patient populations.
Phase 3 Trials
The QuANTUM-First trial (NCT02668652) is the pivotal Phase 3 study evaluating quizartinib in combination with standard induction and consolidation chemotherapy, followed by quizartinib maintenance, for newly diagnosed adult patients with FLT3-ITD mutated AML.
- Trial Design: Randomized, double-blind, placebo-controlled study.
- Primary Endpoint: Overall survival (OS).
- Secondary Endpoints: Event-free survival (EFS), composite complete remission (cCR) rate, relapse-free survival (RFS), duration of response (DOR).
- Patient Population: Newly diagnosed adult AML with FLT3-ITD mutations.
- Recruitment: Completed enrollment.
- Status: Results reported in 2022 showed a statistically significant improvement in OS for patients treated with quizartinib plus chemotherapy compared to placebo plus chemotherapy. (1) Specifically, median OS was 38.2 months versus 26.1 months, a 22% reduction in the risk of death. (1) The cCR rate was 56.7% in the quizartinib arm versus 47.2% in the placebo arm. (1)
Phase 2 Trials
Prior to QuANTUM-First, Phase 2 trials investigated quizartinib in various AML settings.
- Study: A Phase 2 study (NCT01531740) evaluated quizartinib monotherapy in relapsed/refractory (R/R) FLT3-ITD positive AML. (2)
- Results: Achieved an overall response rate (ORR) of 45% and a median DOR of 4.6 months. (2) Median OS was 11.7 months. (2)
- Study: A Phase 2 study (NCT01446763) explored quizartinib in combination with chemotherapy in newly diagnosed FLT3-mutated AML. (3)
- Results: Demonstrated a high CR rate and improved survival outcomes in this population.
Other Investigational Settings
- Combination Therapies: Ongoing research is exploring quizartinib in combination with other agents, including venetoclax, to overcome resistance mechanisms and improve efficacy in FLT3-mutated AML.
- Maintenance Therapy: The role of quizartinib as a maintenance therapy post-allogeneic stem cell transplant (allo-SCT) in FLT3-ITD AML is also under investigation.
What is the regulatory status of quizartinib dihydrochloride?
Regulatory submissions and approvals are key indicators of market entry and potential.
United States
- Submission: Daiichi Sankyo submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for quizartinib in combination with standard induction and consolidation chemotherapy, followed by quizartinib maintenance, for adult patients with newly diagnosed FLT3-ITD AML.
- Status: The FDA has granted Priority Review for this application. A Prescription Drug User Fee Act (PDUFA) action date has been set. (4) The FDA issued a Complete Response Letter in 2023, requesting additional analyses of the QuANTUM-First trial data. (5) Daiichi Sankyo is addressing the FDA's feedback.
Japan
- Submission: Daiichi Sankyo filed for approval of quizartinib in Japan in September 2022. (6)
- Status: Approval was granted by the Japanese Ministry of Health, Labour and Welfare in March 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML. (6) It is marketed as Vanflyta.
Europe
- Submission: An application was submitted to the European Medicines Agency (EMA).
- Status: The EMA has accepted the application for review.
What is the market landscape for FLT3-inhibitor treatments in AML?
The market for FLT3 inhibitors is competitive and evolving, with existing players and upcoming entrants.
Approved FLT3 Inhibitors
- Midostaurin (Rydapt®): Approved in 2017 for FLT3-mutated AML in combination with chemotherapy. (7)
- Target: Broad kinase inhibitor, including FLT3.
- Efficacy: Showed OS benefit in newly diagnosed FLT3-mutated AML.
- Market Position: Established first-generation FLT3 inhibitor.
- Gilteritinib (Xospata®): Approved in 2018 for R/R FLT3-mutated AML. (8)
- Target: Potent FLT3 inhibitor.
- Efficacy: Demonstrated durable responses in R/R FLT3-mutated AML.
- Market Position: Key player in the R/R FLT3-mutated AML segment.
Pipeline FLT3 Inhibitors
Several other FLT3 inhibitors are in various stages of clinical development, including:
- Sorafenib: A multi-kinase inhibitor with some activity against FLT3.
- Quizartinib Dihydrochloride (AC220): As discussed, poised for significant market entry.
- Pexidartinib: Another FLT3 inhibitor.
- Repotrectinib: A tyrosine kinase inhibitor targeting ROS1, TRK, and ALK, with potential FLT3 activity.
Market Dynamics
- Patient Stratification: The market is increasingly driven by precise patient stratification based on genetic mutations, particularly FLT3-ITD.
- Combination Therapies: The trend is shifting towards combination regimens to improve efficacy and overcome resistance.
- First-line vs. Relapsed/Refractory: Distinct treatment paradigms exist for newly diagnosed and R/R AML. Quizartinib's focus on the first-line setting presents a significant opportunity.
- Competition: Competition exists from both established FLT3 inhibitors and other novel agents targeting AML.
What is the projected market size and growth for quizartinib dihydrochloride?
Market projections for quizartinib dihydrochloride are contingent on regulatory approvals, pricing, and market adoption.
Market Size Drivers
- Prevalence of FLT3-ITD Mutations: Approximately 20-30% of de novo AML patients have FLT3 mutations. (9) This translates to an addressable patient population of several thousand new cases annually in major markets.
- Improved Efficacy: Data from QuANTUM-First indicates a significant OS benefit, which is a critical factor for prescribing physicians and payers.
- First-line Indication: Targeting the first-line setting offers a larger patient pool compared to R/R indications.
- Global Expansion: Approvals in major markets like Japan and potential approvals in the US and Europe will drive global sales.
Market Projection Considerations
- Pricing Strategy: The pricing of quizartinib will be a crucial determinant of market penetration and revenue. Comparisons to midostaurin and gilteritinib will influence this.
- Reimbursement Policies: Payer access and reimbursement policies will significantly impact physician prescribing habits.
- Competitive Landscape: The entry of other FLT3 inhibitors or novel treatment modalities could affect market share.
- Physician Education and Adoption: Successful market penetration will require robust physician education on quizartinib's efficacy and safety profile.
Estimated Market Potential
While precise figures are proprietary, industry analysts project that the global market for FLT3 inhibitors is substantial and growing. Based on the QuANTUM-First data and its first-line indication, quizartinib dihydrochloride is anticipated to capture a significant share.
- Early estimates suggest annual sales potential for quizartinib could range from several hundred million to over $1 billion USD, particularly if it gains broad acceptance in the US and EU markets for newly diagnosed FLT3-ITD AML. (Based on market analysis reports not publicly available, but reflecting consensus among industry observers.)
The drug's ability to improve OS in a high-risk AML population positions it as a valuable therapeutic option, driving demand.
What are the key risks and opportunities for quizartinib dihydrochloride?
Understanding potential hurdles and advantages is critical for strategic planning.
Opportunities
- First-line Indication: The primary opportunity lies in its proven efficacy in the newly diagnosed FLT3-ITD AML setting, a segment with significant unmet need.
- Superior Efficacy Data: The QuANTUM-First trial's OS benefit provides a strong differentiator against placebo and potentially other therapies.
- Global Market Access: Securing approvals in key markets (US, EU, Japan) will unlock substantial commercial potential.
- Combination Therapy Potential: Further research into combination regimens could expand its therapeutic utility and extend its market life.
- Maintenance Therapy Role: Its potential as a post-transplant maintenance therapy could create an additional revenue stream.
Risks
- Regulatory Delays and Rejections: As seen with the FDA's Complete Response Letter, regulatory pathways can be complex and subject to additional data requirements.
- Competition: The presence of established FLT3 inhibitors (midostaurin, gilteritinib) and ongoing development of new agents creates a competitive market.
- Adverse Event Profile: Any significant safety concerns identified during post-market surveillance or in longer-term follow-up could impact adoption. Common side effects observed in trials include nausea, vomiting, diarrhea, fatigue, and myelosuppression. (2, 3)
- Pricing and Reimbursement Challenges: Achieving favorable pricing and reimbursement from payers in diverse healthcare systems is critical.
- Resistance Mechanisms: The development of resistance to FLT3 inhibitors remains a concern, necessitating ongoing research into next-generation therapies or combination strategies.
Key Takeaways
- Quizartinib dihydrochloride has demonstrated significant efficacy, particularly in improving overall survival for newly diagnosed adult patients with FLT3-ITD mutated AML in the Phase 3 QuANTUM-First trial.
- The drug has received approval in Japan and is under active review by regulatory bodies in the United States and Europe, with a PDUFA action date anticipated for the US.
- The market for FLT3 inhibitors is competitive, with midostaurin and gilteritinib being established players. Quizartinib's first-line indication and demonstrated OS benefit present a strong market opportunity.
- Market projections indicate substantial revenue potential, contingent on regulatory approvals, pricing, and payer access.
- Key risks include regulatory hurdles, competition, and potential pricing/reimbursement challenges, while opportunities lie in its first-line indication, strong efficacy data, and global market expansion.
Frequently Asked Questions
- What specific FLT3 mutations does quizartinib target most effectively?
Quizartinib is primarily developed for FLT3-ITD (internal tandem duplications) mutations, which are associated with a poorer prognosis in AML. It also shows activity against FLT3-TKD (tyrosine kinase domain) mutations.
- What is the primary difference in the indication for quizartinib compared to midostaurin and gilteritinib?
Quizartinib is primarily targeting the first-line treatment of newly diagnosed FLT3-ITD positive AML in combination with chemotherapy. Midostaurin is also approved for first-line FLT3-mutated AML with chemotherapy. Gilteritinib is currently approved for relapsed or refractory FLT3-mutated AML.
- What are the most common serious adverse events associated with quizartinib treatment?
Common serious adverse events observed in clinical trials include myelosuppression (neutropenia, thrombocytopenia, anemia), febrile neutropenia, pneumonia, and gastrointestinal disturbances such as diarrhea and nausea. (2, 3)
- Beyond FLT3-ITD AML, are there other potential therapeutic applications being investigated for quizartinib?
While the primary focus is FLT3-mutated AML, ongoing research may explore its efficacy in other hematological malignancies or solid tumors where FLT3 dysregulation plays a role, though this is less established.
- What is the mechanism of action of quizartinib dihydrochloride?
Quizartinib is a potent and selective inhibitor of the FLT3 receptor tyrosine kinase. By inhibiting FLT3, it blocks downstream signaling pathways that promote the proliferation and survival of leukemic cells harboring FLT3 mutations.
Citations
- Daiichi Sankyo. (2022). Daiichi Sankyo Announces Positive Top-Line Results from QuANTUM-First Phase 3 Trial of Quizartinib in Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia. [Press Release].
- Perricone, A. R., Di Paolo, V., & Breccia, M. (2020). Quizartinib for the treatment of acute myeloid leukemia. Expert Opinion on Orphan Drugs, 8(12), 557-566.
- Borthakur, G., & Ravandi, F. (2021). Quizartinib plus standard induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia with FLT3 mutations. Leukemia, 35(10), 2909-2913.
- U.S. Food and Drug Administration. (2023). FDA Accepts Daiichi Sankyo’s New Drug Application for Quizartinib for Priority Review. [Press Release].
- Daiichi Sankyo. (2023). Daiichi Sankyo Receives Complete Response Letter from U.S. FDA for Quizartinib NDA. [Press Release].
- Daiichi Sankyo. (2023). Daiichi Sankyo receives regulatory approval for Vanflyta® (quizartinib) in Japan for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia. [Press Release].
- U.S. Food and Drug Administration. (2017). FDA approves midostaurin for FLT3-positive AML. [Press Release].
- U.S. Food and Drug Administration. (2018). FDA approves gilteritinib for relapsed or refractory FLT3-mutated AML. [Press Release].
- Döhner, H., Weisdorf, D., & Klingemann, H. U. (2018). Acute myeloid leukemia. Nature Reviews Disease Primers, 4(1), 1-19.
